HC Wainwright Issues Optimistic Forecast for UNCY Earnings

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – Analysts at HC Wainwright increased their Q3 2026 earnings per share (EPS) estimates for shares of Unicycive Therapeutics in a research report issued on Tuesday, September 29th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.39) for the quarter, up from their prior estimate of ($0.40). HC Wainwright currently has a “Buy” rating and a $13.00 target price on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($1.16) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2026 earnings at ($0.39) EPS, FY2026 earnings at ($1.38) EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.28) EPS, Q3 2027 earnings at ($0.19) EPS, Q4 2027 earnings at $0.04 EPS, FY2027 earnings at ($0.86) EPS, FY2028 earnings at $2.85 EPS, FY2029 earnings at $3.75 EPS and FY2030 earnings at $4.98 EPS.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.41.

Other equities analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Zacks Research raised Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Wednesday, August 19th. B. Riley Financial restated a “buy” rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Benchmark reaffirmed a “speculative buy” rating and set a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a research report on Thursday, August 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Unicycive Therapeutics in a research note on Friday, September 4th. Five research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Unicycive Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.25.

Unicycive Therapeutics Price Performance

NASDAQ:UNCY opened at $4.55 on Thursday. Unicycive Therapeutics has a one year low of $3.93 and a one year high of $8.74. The company’s 50-day simple moving average is $5.12 and its 200 day simple moving average is $6.27. The firm has a market capitalization of $126.72 million, a P/E ratio of -2.60 and a beta of 1.83.

Institutional Investors Weigh In On Unicycive Therapeutics

A number of institutional investors have recently made changes to their positions in UNCY. Renaissance Technologies LLC bought a new stake in shares of Unicycive Therapeutics during the first quarter valued at approximately $161,000. Bank of America Corp DE lifted its position in Unicycive Therapeutics by 19,327.6% in the 1st quarter. Bank of America Corp DE now owns 29,530 shares of the company’s stock valued at $194,000 after acquiring an additional 29,378 shares in the last quarter. Bank of New York Mellon Corp bought a new position in Unicycive Therapeutics in the 2nd quarter valued at approximately $248,000. Seven Fleet Capital Management LP purchased a new stake in Unicycive Therapeutics during the 1st quarter valued at $367,000. Finally, Dimensional Fund Advisors LP purchased a new stake in Unicycive Therapeutics during the 1st quarter valued at $940,000. Hedge funds and other institutional investors own 40.42% of the company’s stock.

Unicycive Therapeutics News Roundup

Here are the key news stories impacting Unicycive Therapeutics this week:

• Positive Sentiment: HC Wainwright reiterated a Buy rating and $13 price target, substantially above Unicycive’s recent trading level. The firm raised several longer-term EPS forecasts, including estimates of $2.85 for fiscal 2028, $3.75 for 2029 and $4.98 for 2030, reflecting expectations for improving commercialization and profitability. Some near-term quarterly and fiscal estimates were also improved, although the company is still expected to post losses through fiscal 2027. HC Wainwright earnings estimates
• Neutral Sentiment: Unicycive appointed Meredith Manning, M.B.A., to its board of directors. The addition may strengthen the company’s governance and strategic expertise, but the announcement provided no immediate change to the company’s clinical, regulatory or financial outlook. Unicycive appoints Meredith Manning
• Negative Sentiment: Multiple law firms publicized a securities class action against Unicycive and certain officers, with a November 2, 2026 deadline for investors to seek lead-plaintiff status. The allegations concern the company’s use of a contract manufacturer that had been cited by the FDA for current good manufacturing practice deficiencies, allegedly without confirming compliance. The lawsuit claims the unresolved issues contributed to a second Complete Response Letter and a reported 39.1% one-day share-price decline. These are allegations and have not been proven in court. Unicycive shareholder class action alert
• Negative Sentiment: HC Wainwright’s separate report reduced its Q1 2027 EPS forecast to a $0.43 loss from a $0.31 loss, and another report indicated the firm cut its price target, adding a modestly negative near-term signal despite the continued Buy rating.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for patients with kidney disease. The company’s lead product candidate is oxylanthanum carbonate, an oral phosphate binder being developed to treat hyperphosphatemia, or elevated phosphate levels, in patients with chronic kidney disease, including those receiving dialysis.

Oxylanthanum carbonate is designed to bind dietary phosphate in the gastrointestinal tract, helping reduce the amount of phosphate absorbed into the bloodstream.